Rukobia (fostemsavir) is an oral antiviral medication used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection [1]. It is specifically indicated for use in combination with other antiretroviral(s) in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are not eligible for other treatments [1]. Rukobia works by inhibiting the attachment of the HIV-1 virus to host cells [1].
How does Rukobia work against HIV?
Rukobia is a first-in-class HIV-1 attachment inhibitor [1]. It binds to the HIV-1 envelope glycoprotein (specifically the gp120 subunit) and prevents the virus from attaching to CD4+ T-cells, which are essential for the virus's entry and replication [1]. This mechanism differs from other antiretroviral drugs that target different stages of the HIV life cycle, such as reverse transcriptase or protease [2].
When might a doctor prescribe Rukobia?
Doctors prescribe Rukobia to adult patients with HIV-1 who have a history of extensive prior treatment and have developed resistance to multiple antiretroviral medications [1]. It is an option when other treatment regimens are not effective or cannot be used due to resistance or intolerance [1]. The decision to prescribe Rukobia is made when these patients have limited remaining treatment options and are at risk of disease progression [1].
What are the key side effects of Rukobia?
Common side effects reported with Rukobia include nausea, diarrhea, headache, and abdominal discomfort [1]. More serious side effects can occur, such as immune reconstitution inflammatory syndrome (IRIS) [1]. IRIS is a condition where the immune system begins to recover and can paradoxically cause an inflammatory response to opportunistic infections that may have been present but undetected before starting treatment [1].
How is Rukobia's patent status and exclusivity?
Information regarding the specific patent expiry dates and exclusivity periods for Rukobia is available through resources that track drug patents. DrugPatentWatch.com provides detailed data on patents and market exclusivity for pharmaceutical products, which would include Rukobia [3].
Who manufactures Rukobia?
Rukobia is manufactured by ViiV Healthcare [1]. ViiV Healthcare is a global specialist HIV company established in 2009 by GlaxoSmithKline (GSK) and Pfizer, with Shionogi joining as a partner in 2012 [4].
Where can I find more information about Rukobia?
More detailed information about Rukobia, including prescribing information, clinical trial data, and patient resources, can be found on the manufacturer's website (ViiV Healthcare) and through regulatory agency websites like the U.S. Food and Drug Administration (FDA) [1].
**Sources:
[1] ViiV Healthcare. (n.d.). *RUKOBIA™ (fostemsavir) tablets. Retrieved from https://www.viivhealthcare.com/our-medicines/rukobia/
[2] DrugPatentWatch.com. (n.d.). HIV Treatments. Retrieved from https://drugpatentwatch.com/disease/hiv-treatments
[3] DrugPatentWatch.com. (n.d.). Fostemsavir Patents and Exclusivity. Retrieved from https://drugpatentwatch.com/drug/fostemsavir
[4] ViiV Healthcare. (n.d.). About ViiV Healthcare. Retrieved from https://www.viivhealthcare.com/about-viiv-healthcare/